Novel Lipid Nanoparticle Delivery Reagent And Rapid Manufacturing Workflow To Accelerate Preclinical Development Of RNA Vaccines

iStock-1293772874-lab-plasmid-gene therapy-DNA

The biggest vaccine campaign in history is ongoing against COVID-19, with RNA vaccines playing a key role. Due to the rapid degradation of RNA and low cellular uptake, an essential element of RNA vaccines are lipid nanoparticle (LNP) delivery systems. Limited access to ionizable lipids and LNP compositions, and the difficulty in scale-up production of RNA-LNPs remain challenges in the field. In this study, we aim to highlight that commercially available LNP reagent mix, GenVoy-ILM, is an accessible and easy-to-use LNP formulation that allows for rapid preclinical development of RNA vaccines.

access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene